NASDAQ OMX

Salt Institute : 2018 World Salt Symposium to Feature 500 International Experts

Dela

Groundbreaking Evidence on Salt and Health

 

Park City, Utah, USA, June 11, 2018 (GLOBE NEWSWIRE) -- The Tenth World Salt Symposium will be held June 19-21, 2018 in Park City, Utah, and will feature nearly 100 presentations from around the globe covering all topics related to salt. Starting in the 1960's, people from around the world have gathered to share information on the health benefits and uses of salt, salt mining practices, and solar salt production. The last such meeting was held in Beijing, China in 2009. The extended period between these conferences ensures a far-reaching and inclusive technical content. This is, without doubt, the most important international meeting focused on the subject of salt with 500 international visitors registered to attend.

Organized and hosted by the Salt Institute, in cooperation with several other salt organizations around the world, the World Salt Symposium focuses on the latest research and development in the international salt sector. It covers a wide spectrum of subjects, embracing the science, engineering, technology, economics and history of all forms of sodium chloride salt and their uses. As a broad international platform, the 2018 World Salt Symposium will enable researchers, producers and users of salt to become acquainted with the latest developments and technologies in this important industrial area. 

Four of the world's top scientists on cardiovascular health outcomes will gather for a frank discussion on salt and health. They will focus on the need for large randomized controlled trials on the impact of salt on health outcomes before any population wide sodium reduction recommendation can be made. The panel will include Dr. Michael H. Alderman, MD, Albert Einstein College of Medicine, Dr. Andrew Mente PhD, MA, McMaster University, David A. McCarron, MD, FACP, FAHA, University of California, Davis, and Professor Jan A. Staessen, MD, PhD, University of Leuven.

Other topics will include the importance of iodized salt for thyroid health, new technology in winter maintenance for environmental road salting, and new techniques in various types of salt production. The last category will include mine safety. Experts will present on issues ranging from the history of salt production in the ancient world to maintaining the integrity of modern salt caves used to store the US Strategic Petroleum Reserve. 

"We are pleased to bring the World Salt Symposium back to the United States and to host this important event. The Salt Institute is also happy to announce that we have made our 55-year-old World Salt Symposia archive available on a new website that will serve as a permanent and public archive of all past and future papers presented at World Salt Symposia," said Lori Roman, President of the Salt Institute. Keynote sessions will be live streamed on the World salt Symposium YouTube page (http://bit.ly/salt2018). Learn more and see the full agenda at www.worldsaltsymposium.org

-30-

The Salt Institute is a North American based non-profit trade association dedicated to advancing the many benefits of salt, particularly to ensure winter roadway safety, quality water and healthy nutrition.

Jorge Amselle
Salt Institute
703-896-0131
jorge@saltinstitute.org



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Salt Institute via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Corline Biomedical AB: Läkemedelsverket ger tillstånd till klinisk prövning av Renaparin®6.8.2018 15:29Pressmeddelande

Corline Biomedical AB ("Corline") har i beslutsbrev från Läkemedelsverket erhållit tillstånd att genomföra klinisk prövning av läkemedelskandidaten Renaparin®. Läkemedelsverkets tillståndsmeddelande innebär att samtliga formella krav är uppfyllda för genomförande av studien RENAPAIR 01, som är en säkerhetsstudie i fas 1 omfattande totalt 18 patienter. Renaparin® är under utveckling för att förbättra njurtransplantation och administreras till njuren före transplantation i syfte att minska njurskador som annars kan uppstå då den mottagande patientens blodflöde kopplas ihop med donator-njuren. Corline meddelade i juni 2018 att man till Läkemedelsverket inlämnat ansökan om att få genomföra klinisk prövning av Renaparin® i en placebo-kontrollerad studie (RENAPAIR 01, Eudra-CT 2017-002075-25) där 9 patienter transplanteras med njurar som erhållit aktiv substans och 9 patienter får overksam placebo. Denna ansökan har nu godkänts av Läkemedelsverket. Studien inleds i Uppsala och genomförs däre

Cisco Schedules Conference Call for Q4 and Fiscal Year 2018 Financial Results1.8.2018 22:30Pressmeddelande

SAN JOSE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Cisco has scheduled a conference call for Wednesday, August 15, 2018, at 1:30 PM (PT); 4:30 PM (ET) to announce its fourth quarter and fiscal year 2018 financial results for the period ending Saturday, July 28, 2018. Financial results will be released over GlobeNewswire via US National, European Technology Trade Media and Western Europe distribution circuits, after the close of the market on Wednesday, August 15, 2018. Cisco's quarterly earnings press release will be posted at www.cisco.com under the "Newsroom" section. Date: Wednesday, August 15, 2018 Time: 1:30 PM (PT); 4:30 PM (ET) To Listen via Telephone: 888-848-6507 212-519-0847 (for International Callers) RSVP: No RSVP is necessary To Listen via the Internet: We are pleased to offer a live and replay audio broadcast of the conference call with corresponding slides at https://investor.cisco.com. Replay: A telephone playback of the Q4 and FY2018 conference call is scheduled to be

Corline Biomedical AB: Corline erhåller andra utbetalningen från EU-kommissionen31.7.2018 08:45Pressmeddelande

Corline Biomedical AB ("Corline") meddelade i november 2016 att EU-kommissionen beslutat anslå ca 2,4 MEUR (ca 23,1 MSEK) till bolagets kliniska studie inom njurtransplantation med läkemedelskandidaten Renaparin ® . En första utbetalning från H2020-programmet till Corline om ca 1,2 MEUR genomfördes i mars 2017. Corline har nu sammanställt en rapport till EU-kommissionen i vilken framgår att samtliga delmål i projektets första fas är uppnådda. Därmed har kommissionen beslutat om fortsatt stöd och en andra delbetalning om ca 1 MEUR utbetalas inom kort. Corline erhåller anslaget för att genomföra den planerade kliniska fas 1-studien för Renaparin® som är under utveckling för att förbättra njurtransplantation. Den första projektfasen har bland annat innefattat GMP-produktion av läkemedelssubstansen och upprättande av ansökan om klinisk prövning samt inlämnande av densamma till Läkemedelsverket. Samtliga delmål i den första projektfasen har uppfyllts och rapporteringen om dessa har nu grans

RFA Accelerates Growth with Expansion in Luxembourg30.7.2018 15:00Pressmeddelande

RFA announces new private financial cloud in Luxembourg to accelerate growth and accommodate increased demand in technology regulation and cybersecurity LUXEMBOURG, July 30, 2018 (GLOBE NEWSWIRE) -- RFA, a next-gen managed IT service provider for the financial industry, announces a new private financial cloud in Luxembourg. This expansion allows RFA to accommodate accelerated growth in Europe and offer a portfolio of high quality private cloud services to both its existing and new financial services clients in Luxembourg, Madrid, Paris, and the wider region. Along with the London office, the new office doubles RFA's footprint in Europe and further bolsters the company's growth strategy. RFA has two highly secure, tier-one data centres in Luxembourg which meet the ISO27001 and SSAE16/Type II standards, which is key for firms regulated by the Commission de Surveillance du Sector Financier (CSSF). RFA is now ideally placed to provide a range of services to clients in this region, and offe

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum